Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
21.12.2023 16:22:57 CET | ViroGates | Company Announcement
COMPANY ANNOUNCEMENT - No. 25-2023 - 21 December 2023
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today publishes the financial calendar for 2024 with the following key dates:
21 March 2024 | Annual Report 2023 |
4 April 2024 | Deadline for submission of business to be transacted at the 2024 Annual General Meeting |
25 April 2024 | Annual General Meeting |
2 May 2024 | Interim Report Q1 2024 |
15 August 2024 | Interim Report H1 2024 |
7 November 2024 | Interim Report Q1-Q3 2024 |
The interim and annual financial reports will be available on ViroGates’ website (www.virogates.com) immediately after release.
ViroGates encourages all shareholders to sign up to receive relevant shareholder information at its shareholder portal (www.virogates.com/shareholder-portal).
Written requests to have specific business transacted at the Annual General Meeting will be included in the agenda if received by the company no later than 4th April 2024 via email to jk@virogates.com or jbj@virogates.com
For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: ca@vhcorp.se
About ViroGates
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff as well as to monitor health in the general population.
The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
Disclosure regulation
Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.
Contacts
- Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com